Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting
  • Home
  • Signaling Pathways

Signaling Pathways

Items 91-100 of 108

Page
per page
  1. Y-27632 dihydrochloride
    A3008 Y-27632 dihydrochloride
     19 Citation
    Target: ROCK
    Summary: ROCK1 inhibitor
      ≥111.2 mg/mL
  2. Dasatinib (BMS-354825)
    A3017 Dasatinib (BMS-354825)
     4 Citation
    Summary: Src and BCR-Abl inhibitor
      ≥24.4 mg/mL
  3. (-)-Epigallocatechin gallate (EGCG)
    A2600 (-)-Epigallocatechin gallate (EGCG)
    Target: BACE
    Summary: Antioxidant, antiangiogenic and antitumor agent
      ≥22.9 mg/mL
  4. A 77-01
    A3132 A 77-01
    Summary: Potent ALK5 inhibitor
      insoluble in H2O; ≥14.3 mg/mL
  5. A 83-01
    A3133 A 83-01
    Summary: ALK-5 inhibitor
      ≥21.1 mg/mL
  6. Chelerythrine Chloride
    A3306 Chelerythrine Chloride
    Target: PKC
    Summary: PKC antagonist
      insoluble in H2O; ≥19.2 mg/mL
  7. chroman 1
    A3310 chroman 1
     1 Citation
    Summary: ROCK II inhibitor, highly potent and selective
      ≥50.3 mg/mL
  8. Hydroxyfasudil
    A3478 Hydroxyfasudil
    Target: ROCK|Rho-kinase
    Summary: Rho-kinase inhibitor and vasodilator
      Soluble in DMSO
  9. Hydroxyfasudil hydrochloride
    A3479 Hydroxyfasudil hydrochloride
    Summary: Rho-kinase inhibitor and vasodilator
      insoluble in EtOH; ≥7.88 mg/mL
  10. LDN193189 Hydrochloride
    A3545 LDN193189 Hydrochloride
     1 Citation
    Summary: ALK inhibitor,potent and selective
      ≥27.6 mg/mL

Items 91-100 of 108

Page
per page